Breathing New Life into Clinical Trials

Breathing New Life into Clinical Trials

Using AI to solve some of the greatest barriers to healthcare innovation: clinical trial recruitment and retention



In the most recent issue of Delta Magazine, Natasha Cowan talked with our CEO Wout Brusselaers about Deep 6 AI, our technology, and the clinical trial industry pain points it addresses.


When asked how the Deep 6 AI software works, Wout explained that our clinical trial acceleration software provides the connective tissue between all clinical trial stakeholders: research staff, care staff, patients, collaborating partners, and sponsors. The capabilities and real-time data empower stakeholders with a holistic view of the patient, and it helps to overcome several of the most significant barriers to clinical trial recruitment: up to 90% of patient data is unstructured (free text in EMRs, lab data, medication records, registry data, pathology or ‘-omics’), and the data are found in separate, siloed systems. It’s no wonder it’s a monumental task.


By using artificial intelligence (AI) methods such as natural language processing (NLP) and machine learning (ML), our software analyzes both the structured and unstructured data, fitting the data into a model that helps to identify patterns and correlations in those data, rather than just looking strictly for search terms. Because of this and the ability to query data from multiple systems, it brings together all the relevant information from the patient’s entire clinical journey — from initial tests to the final diagnosis and beyond. 


Wout discussed the importance of building trust with patients and bringing awareness about the clinical trials available to them. Our software enables care providers to offer validated studies as a care option by precision matching the patient to a study’s inclusion/exclusion criteria. This ensures shared decision-making among all stakeholders in the clinical trial ecosystem and empowers the treating physician, nurses, and patient. 


The COVID-19 pandemic was described as a “wake-up call” to health systems to change the status quo in order to be crisis-robust. Organizations need to ensure their research is data-driven and digital. Having a connected, digital ecosystem brings value, as it enables sponsors, research staff, care staff, and patients to communicate closely despite being in different locations. Connecting the research and care teams boosts patient recruitment. 


Lastly, Wout talked about our company’s future. We’re expanding our focus to life science companies, having them join our real-time, real-world data ecosystem. We have rich, robust data across a large (and growing) collection of research centers that allow us to “drive meaningful interactions” based on statistically significant data. We’re continuing to deepen our understanding of patient data in order to create clearer, more precise patient profiles and to develop an even stronger dataset. 


Wout said, “There is this exciting, creative part of being the outsider that somehow allowed us to build something really innovative and new that ‘insiders’ perhaps hadn’t thought of or dismissed, because, unlike us, they knew how hard it would be. Maybe we took the longest route, but now we have built this amazing solution and we’re on the cusp of unlocking its value for all participants. I think it’s pretty unrivaled. The unstructured data mining, the ecosystem, the collaborative workflows… I don’t think there’s much like it out there.”


To read the interview, check out Delta Magazine.



To see for yourself how Deep 6 AI’s patient recruitment software can match patients to clinical trials in minutes, not months, schedule a demo today.